drugset / Trial / NCT01079988
Study of Therapeutic Options for Subjects Discontinuing Efalizumab and Experiencing Disease Recurrence
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a pilot investigational study of the appropriate therapeutic regimens to treat subjects experiencing inflammatory recurrence (rebound) of psoriatic disease upon discontinuation of efalizumab therapy and of the biological mechanisms involved in inflammatory disease recurrence and control.
Timeline
- Start
- 2004-02
- Primary completion
- 2004-12
- Completion
- 2005-04
Publications
- Results Papp KA, Toth D, Rosoph L, on behalf of the 25180 study group. Approaches to discontinuing efalizumab: results of an open-label study comparing different transitioning therapies. Abstract for presentation at EADV2005, Sofia, Bulgaria, 19-22 May 2005
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Methotrexate | Small molecule | 20 mg | — |
| Subject | Methotrexate | Small molecule | 25 mg | — |